TRT After 50: Benefits, Risks, Blood Pressure, and FDA Label Updates

September 1, 2026Atlanta Medical Institute

Testosterone therapy after 50 requires balanced, clinician-led decisions. See what the FDA changed in labeling, potential benefits and risks, and why blood-pressure monitoring matters.

Published 2026-09-01

Testosterone replacement therapy in men over 50 is a frequent discussion topic in Atlanta. This article explains what changed in U.S. Food and Drug Administration testosterone labeling, which potential benefits and risks men with confirmed hypogonadism may discuss with a clinician, and why blood-pressure monitoring matters throughout therapy. It is designed to support an informed conversation with your care team at Atlanta Medical Institute. Do not start, stop, or change any prescription medication or hormone therapy without guidance from the prescribing clinician.

What changed in FDA testosterone labeling?

Testosterone products are approved to treat men who have low testosterone caused by certain medical conditions, not for age-related testosterone decline alone [4]. In 2015, the FDA required labeling to clarify this limited indication and to inform patients and clinicians about a possible increased risk of heart attack and stroke, based on then-available data [7].

More recently, the FDA announced class-wide labeling changes for all testosterone products. These updates included information about increases in blood pressure observed with testosterone therapies and aligned cardiovascular safety language across the class [1]. The FDA also described how newer evidence has informed labeling and emphasized use only for men with confirmed hypogonadism due to specific causes [5, 4].

Individual product labels may carry additional, formulation-specific warnings. For example, the approved oral testosterone undecanoate capsule label highlights increases in blood pressure and the potential for increased risk of major adverse cardiovascular events, with instructions for clinicians to monitor blood pressure during therapy [2].

Potential benefits men with confirmed hypogonadism may discuss

When low testosterone is confirmed with appropriate testing and linked to specific medical causes, testosterone therapy may improve certain symptoms and health measures. Clinical guidelines and professional statements describe potential benefits that can include improved sexual function, increased libido, better erectile function, improved mood or sense of well-being in some men, increased lean body mass with decreased fat mass, and improvements in bone mineral density over time [12, 6].

Responses vary. Professional societies emphasize individualized decision-making that weighs symptom burden, laboratory confirmation, comorbidities, and personal priorities in collaboration with a qualified clinician [6, 12].

Potential risks, cautions, and why monitoring matters after 50

Cardiovascular outcomes: A large randomized, placebo-controlled trial in men with hypogonadism and elevated cardiovascular risk found that testosterone therapy was noninferior to placebo for major adverse cardiovascular events, informing recent FDA labeling changes [3, 5]. In that study, certain adverse events, including atrial fibrillation and pulmonary embolism, occurred more often in the testosterone group, underscoring the importance of individualized risk assessment and monitoring [3].

Blood pressure: The FDA’s class-wide update highlights that testosterone therapy can raise blood pressure in some patients, and labels instruct clinicians to monitor blood pressure during treatment [1, 2]. Monitoring is important because elevated blood pressure adds cardiovascular risk over time, and real-world responses can differ across individuals [1, 2]. Ambulatory and clinic blood-pressure studies in men using transdermal formulations report mixed findings, reinforcing the need for ongoing measurement rather than assumptions [8, 9, 10].

Other safety considerations: Clinicians commonly discuss and monitor for erythrocytosis (elevated hematocrit), sleep-apnea symptoms, acne or oily skin, gynecomastia, fertility considerations, and prostate-related questions as part of a broader risk–benefit conversation guided by established clinical practice recommendations [12].

Men over 50 often have additional health factors—such as cardiovascular risk, medications for chronic conditions, or sleep and metabolic concerns—that shape whether testosterone therapy is appropriate and how it is monitored. Major organizations encourage a shared, clinician-led approach that weighs these factors and revisits them over time [6, 12].

TRT and blood pressure: what to know before and during therapy

Before therapy: FDA communications advise that testosterone should be used only in men with confirmed hypogonadism caused by specific medical conditions, not for age-related decline, and that product labels now call attention to blood-pressure effects across the class [4, 1]. A conversation with your clinician typically includes a review of your current blood pressure pattern, cardiovascular history, and medications that can influence blood pressure or interact with therapy. If medication adjustments are ever considered, do not make changes without the prescribing clinician; decisions are individualized and clinician-directed [12].

During therapy: Product labels instruct clinicians to monitor blood pressure after starting therapy and during ongoing treatment, because increases can occur even when baseline readings were normal [1, 2]. Evidence from ambulatory and clinic-based studies suggests variability by individual and by formulation, which means routine measurement is a practical safeguard rather than an optional step [8, 9, 10].

Ask how and when your blood pressure will be measured during therapy, including whether home or ambulatory monitoring would add useful context [1, 2].
Review all medications and supplements with your clinician, focusing on agents that can raise blood pressure or interact with testosterone therapy; do not change any medication without the prescribing clinician [12].
Discuss cardiovascular history, including prior arrhythmias, clotting events, or stroke, and how these factors shape the risk–benefit assessment for testosterone therapy in your case [3, 12].
Clarify how symptom changes will be interpreted alongside lab results and vital signs so that decisions remain data-informed over time [6, 12].

Putting the FDA changes in plain English

Testosterone is approved to treat men with hypogonadism due to specific medical conditions confirmed by testing, not age-related low testosterone alone [4, 7].
The FDA updated labels across all testosterone products to highlight blood-pressure effects and to align cardiovascular safety information, drawing on newer data [1, 5].
Individual products may have additional warnings; for example, the oral testosterone undecanoate capsule label includes specific instructions on blood-pressure monitoring [2].

Who may consider testosterone therapy—and who may not

A careful evaluation is important because symptoms such as low energy or decreased libido can have multiple causes. Guidelines recommend confirming low testosterone with appropriate repeat testing and establishing a medical cause before considering therapy [12, 4]. Some men will not be candidates based on their health history; decisions are individualized and made with a clinician who weighs potential benefits against risks and monitoring needs [12, 6].

If you live in the Atlanta area and are preparing for a hormone-health visit at Atlanta Medical Institute, bringing organized questions and recent blood-pressure readings can make the discussion more productive. The clinic’s focus on physician-supervised wellness and anti-aging services provides a setting for evidence-informed conversations about whether testosterone therapy is appropriate in the context of your overall health goals [11].

Questions you can bring to your clinician

Based on my symptoms, labs, and medical history, do I meet criteria for hypogonadism as defined in current guidance, and what else could be contributing to my symptoms [12]?
How do the recent FDA label updates apply to me, and what specific blood-pressure monitoring plan would you recommend if therapy is considered [1, 2]?
What benefits are realistic for someone with my profile, and how will we evaluate whether I am responding over time [12, 6]?
What are the major risks in my case, including cardiovascular, hematologic, sleep, skin, fertility, and prostate considerations, and how will we monitor them [12, 3]?
If we pursue therapy, how might formulation choice influence monitoring priorities, including blood pressure, and what uncertainties should I understand about differences across options such as transdermal gels and oral capsules [1, 2, 8, 9, 10]?
If medication changes become relevant, how should I discuss them with the prescribing clinician, and what should I avoid changing on my own without discussing it first [12]?

Limitations, nuance, and evolving evidence

Even with a large randomized trial informing updated labels, evidence has limits. The major cardiovascular study enrolled men with specific inclusion criteria; its findings may not apply to every age group or risk profile [3]. Observational and ambulatory blood-pressure studies in real-world settings show heterogeneous results across individuals and formulations, making routine monitoring a practical necessity rather than an assumption that blood pressure will rise or remain unchanged [8, 9, 10]. FDA communications continue to emphasize that testosterone therapy is indicated for men with hypogonadism due to certain medical conditions and is not approved for age-related testosterone decline, a boundary that guides responsible use as evidence evolves [4, 7]. Do not start, stop, or change any prescription medication or hormone therapy without the prescribing clinician.

What exactly did the FDA change about testosterone labels?

The FDA updated testosterone labels across the class to highlight blood-pressure effects and to align cardiovascular safety information based on newer evidence; individual products can include additional, formulation-specific warnings. Testosterone remains approved only for men with hypogonadism due to specific medical conditions confirmed by testing, not for age-related decline [1, 5, 4].

What did recent cardiovascular research show about testosterone therapy?

In men with confirmed hypogonadism and elevated cardiovascular risk, a large randomized trial found testosterone therapy noninferior to placebo for major adverse cardiovascular events. However, higher rates of certain adverse events, including atrial fibrillation and pulmonary embolism, were observed with testosterone, so individualized risk assessment remains important [3].

Does testosterone therapy raise blood pressure in everyone?

Class-wide label changes note that testosterone therapy can increase blood pressure, and clinicians are instructed to monitor blood pressure during treatment. Studies using ambulatory and clinic measurements in men on transdermal therapy have reported mixed blood-pressure changes, which is why monitoring is emphasized rather than assuming a uniform effect [1, 2, 8, 9, 10].

Is testosterone therapy used for age-related low testosterone?

Guidelines recommend confirming low testosterone with appropriate repeat testing and identifying a medical cause before considering therapy. The FDA states testosterone products are not approved for treating age-related testosterone decline alone [12, 4].

If I am on blood-pressure medicine, can I consider testosterone therapy?

Medication changes are sometimes considered during care, but any changes should be clinician-directed. If adjustments become relevant, discuss them with the prescribing clinician rather than changing any medication on your own [12].

Sources

When to Talk With a Clinician

Contact Atlanta Medical Institute to discuss your goals, health history, and appropriate options with a qualified clinician.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Medication and hormone-treatment eligibility, risks, monitoring, and results vary; consult a qualified healthcare professional.